EA202090471A1 - Модулирующие т-клетки мультимерные полипептиды и способы их применения - Google Patents

Модулирующие т-клетки мультимерные полипептиды и способы их применения

Info

Publication number
EA202090471A1
EA202090471A1 EA202090471A EA202090471A EA202090471A1 EA 202090471 A1 EA202090471 A1 EA 202090471A1 EA 202090471 A EA202090471 A EA 202090471A EA 202090471 A EA202090471 A EA 202090471A EA 202090471 A1 EA202090471 A1 EA 202090471A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulating
polypeptides
ways
dimensional
application
Prior art date
Application number
EA202090471A
Other languages
English (en)
Inventor
Рональд Д. Сайдел III
Родольфо Дж. Чапарро
Original Assignee
Кью Биофарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кью Биофарма, Инк. filed Critical Кью Биофарма, Инк.
Publication of EA202090471A1 publication Critical patent/EA202090471A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В данном изобретении предложены модулирующие Т-клетки мультимерные полипептиды, содержащие иммуномодулирующий полипептид, который проявляет пониженную аффинность связывания к когнатному ко-иммуномодулирующему полипептиду. Модулирующий Т-клетки мультимерный полипептид является пригодным для модуляции активности Т-клеток, а также для модуляции иммунного ответа у индивидуума.
EA202090471A 2017-09-07 2018-09-06 Модулирующие т-клетки мультимерные полипептиды и способы их применения EA202090471A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555499P 2017-09-07 2017-09-07
PCT/US2018/049756 WO2019051091A1 (en) 2017-09-07 2018-09-06 T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
EA202090471A1 true EA202090471A1 (ru) 2020-06-10

Family

ID=65634643

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090471A EA202090471A1 (ru) 2017-09-07 2018-09-06 Модулирующие т-клетки мультимерные полипептиды и способы их применения

Country Status (13)

Country Link
US (3) US20200148744A1 (ru)
EP (1) EP3678691A4 (ru)
JP (1) JP2020533273A (ru)
KR (1) KR20200040860A (ru)
CN (1) CN111050793A (ru)
AU (1) AU2018328280A1 (ru)
BR (1) BR112020004535A2 (ru)
CA (1) CA3070484A1 (ru)
EA (1) EA202090471A1 (ru)
IL (2) IL297361B2 (ru)
MX (1) MX2020002596A (ru)
TW (1) TW201920248A (ru)
WO (1) WO2019051091A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458096A4 (en) * 2016-05-18 2019-11-27 Cue Biopharma, Inc. T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE
SI3558339T1 (sl) 2016-12-22 2024-05-31 Cue Biopharma, Inc. Celico T modulirajoči multimerni polipeptidi in postopki njihove uporabe
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP7549579B2 (ja) * 2018-12-19 2024-09-11 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節ポリペプチド及びその使用方法
EP3719033A1 (en) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド ＭＡｄＣＡＭ標的化免疫寛容
EP3986448A4 (en) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATOR POLYPEPTIDES AND METHODS OF USE THEREOF
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
MX2022011154A (es) * 2020-03-18 2022-10-13 Gi Innovation Inc Composicion farmaceutica para el tratamiento de cancer que comprende proteina de fusion que se compone de proteina il-2 y proteina cd80 y farmaco anticancerigeno.
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences Inc INTERLEUKIN-2 POLYPEPTIDES AND FUSION PROTEINS THEREOF, AS WELL AS THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用
AU2021271778A1 (en) * 2020-05-12 2022-12-08 Lg Chem, Ltd. Multimeric T-cell modulatory polypeptides and methods of use thereof
KR20230009872A (ko) 2020-05-12 2023-01-17 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
CN116437952A (zh) * 2020-07-14 2023-07-14 库尔生物制药有限公司 具有缀合位点的t细胞调节多肽及其使用方法
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma Inc MHC CLASS II T-CELL MODULATING MULTIMER POLYPEPTIDES FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
WO2023167947A2 (en) * 2022-03-01 2023-09-07 Crosslink Therapeutics Inc. Atp-dependent agonists of immune cells function as anticancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
WO2003048334A2 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
US20170176435A1 (en) * 2014-01-21 2017-06-22 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive t-cell immunomonitoring
HUE048076T2 (hu) * 2014-06-18 2020-07-28 Albert Einstein College Of Medicine Syntac polipeptidek és alkalmazásaik

Also Published As

Publication number Publication date
IL297361B2 (en) 2024-07-01
WO2019051091A1 (en) 2019-03-14
IL272085B (en) 2022-11-01
MX2020002596A (es) 2020-07-20
IL297361A (en) 2022-12-01
AU2018328280A1 (en) 2020-02-13
KR20200040860A (ko) 2020-04-20
EP3678691A4 (en) 2021-06-09
JP2020533273A (ja) 2020-11-19
US20220119483A1 (en) 2022-04-21
IL272085A (en) 2020-03-31
TW201920248A (zh) 2019-06-01
US20240025964A1 (en) 2024-01-25
IL297361B1 (en) 2024-03-01
EP3678691A1 (en) 2020-07-15
IL272085B2 (en) 2023-03-01
US20200148744A1 (en) 2020-05-14
CA3070484A1 (en) 2019-03-14
CN111050793A (zh) 2020-04-21
BR112020004535A2 (pt) 2020-09-08

Similar Documents

Publication Publication Date Title
EA202090471A1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения
PH12019500782A1 (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
CY1122494T1 (el) Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων
IL278091A (en) Heterodimeric 1-PD-targeted OH-FC proteins containing OH-IL-15/IL-15Rα FC proteins and 1-PD antigen binding regions and uses thereof
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
MX2020010061A (es) Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
MX2020005561A (es) Proteinas modificadas de union a adn.
EA201990017A1 (ru) Антитела к миостатину и способы их применения
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
EA201790063A1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
SG10201909716RA (en) Modified j-chain
EP3810172A4 (en) HETERODIMER PROTEINS AND THEIR USES
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2021007479A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
BR112016025450A2 (pt) moduladores de canais de íons e usos dos mesmos
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
MX2020003626A (es) Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.
EP3589652A4 (en) RECOMBINANT ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH 1 (PD-1) AND THEIR USES
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
NZ731491A (en) Cd83 binding proteins and uses thereof
MX2018011193A (es) Proteinas derivadas de alfa-1-microglobulina novedosas y su uso.
EP3677280A4 (en) POLYPEPTIDE AND ANTIBODIES LINKED TO A POLYPEPTIDE